TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04294537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postperative analgesia
Description: During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postperative analgesia
Description: During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours.
Study: NCT03242941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation
Description: After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
Study: NCT03547323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 Dialyzer
Description: An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX80 Dialyzer
Description: An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
Study: NCT02664142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BIS Group
Description: BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-BIS Group
Description: BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaesthetics
Description: Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaesthetics
Description: Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
Study: NCT01834547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drugs use: methylphenidate
Description: 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug use: modafinil
Description: 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01956890

Intervention type: DRUG
Group type: OTHER
Intervention: PET
Description: 18F-FLT PET and MRI of the breast
Study: NCT03351543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbial inoculate
Description: volunteers will regularly receive microbial inoculate that they do not use orally
Study: NCT00430846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35
Description: Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
Study: NCT00904007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Spaced Education (ISE) --- online education
Description: ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions.
Study: NCT04521595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weigh Smart Telehealth intervention
Description: Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
Study: NCT02886923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A Test
Description: contact lens made with hioxifilcon A material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A Test
Description: contact lens made with hioxifilcon A material

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A With Cosmetic Ring Control
Description: contact lens made with hioxifilcon A material with a cosmetic ring on the lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A With Cosmetic Ring Control
Description: contact lens made with hioxifilcon A material with a cosmetic ring on the lens
Study: NCT02443831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19/22 CAR T-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion with fludarabine
Description: Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19/22CAR T-cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion with cyclophosphamide
Description: Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19/22CAR T-cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/22 CAR T-cells
Description: A single dose of 1 x 10\^6/kg CD19/22CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
Study: NCT03151850

Intervention type: OTHER
Intervention: ulcerative colitis
Description: We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.

Intervention type: OTHER
Intervention: Control
Description: We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
Study: NCT00509717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive implementation programme
Description: educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: educational manual
Study: NCT02361866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1107
Description: 0.5 ml, Intramuscular, single dose(day0)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria(Td vaccine)
Description: 0.5ml, Intramuscular, single dose(day0) only applicable step1
Study: NCT01663389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 1000 mg containing radioactive 14C-GSK1322322
Description: GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Description: GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
Study: NCT02862301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Study: NCT01219543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480 Daily
Description: Oral Dose, Capsule, Daily Dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480 BID
Description: Oral Dose, Capsule, BID Dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480 BID
Description: Oral Dose, Capsule, BID Dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480 BID
Description: Oral Dose, Capsule, BID Dosing
Study: NCT02324751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-TCV
Description: Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi-PS Vaccine
Description: Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Control (Men ACWY)
Description: Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
Study: NCT01181973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegvisomant
Description: One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegvisomant
Description: Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegvisomant
Description: Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegvisomant
Description: One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
Study: NCT02373865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin will be given in a daily dosage of 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin-Placebo
Description: Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride-Placebo
Description: Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
Study: NCT00617357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTM (Strattice Reconstructive Tissue Matrix)
Description: Surgical mesh
Study: NCT03792646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Exercise training + 20g whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Strength exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: Strength exercise
Study: NCT00687908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel
Description: Topical Gel to the face, once daily in the evening for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Topical Gel to the face, once daily in the evening for 24 weeks.
Study: NCT00006015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, \& 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
Study: NCT01445249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark guided ankle block.
Description: 25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNS guided block.
Description: This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
Study: NCT02411240

Intervention type: DEVICE
Group type: OTHER
Intervention: Air filtering
Description: The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
Study: NCT02150941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioVac Direct Suction Device
Description: The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endoscopy Suction
Description: Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
Study: NCT03902769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prescribing conventional chemotherapy while with holding allo-SCT
Description: Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prescribing conventional chemotherapy while with holding allo-SCT
Description: Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
Study: NCT03832283

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD-MDD/CAT-DI screening via MyChart
Description: Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD-MDD/CAT-DI screening during clinic visit
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CAD-MDD/CAT-DI screening during clinic visit
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT-DI monitoring via MyChart
Description: Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHQ-9 monitoring during clinic visits
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.

Intervention type: OTHER
Group type: OTHER
Intervention: PHQ-9 monitoring during clinic visits
Description: During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
Study: NCT02674139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T 380A IUD
Description: intrauterine contraceptive device T-shaped loaded with cupper

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T 380A IUD
Description: intrauterine contraceptive device T-shaped loaded with cupper
Study: NCT01791985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547 / anastrozole or letrozole
Description: Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment.
Study: NCT00571623

Intervention type: OTHER
Intervention: Chest Physiotherapy
Description: 10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
Study: NCT01927094

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Comparison of probiotics vs. ORS

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ORS
Description: ORS ad libitum
Study: NCT00499811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03598400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity continous training
Description: Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
Study: NCT01937897

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bi-lateral massage
Description: Unilateral massage on the left side of the body.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bi-lateral massage
Description: Unilateral massage on the left side of the body.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bi-lateral massage
Description: Unilateral massage on the left side of the body.
Study: NCT00372424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
Study: NCT02358057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Study: NCT04549181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II: Problem-Solving for Rural HF Dyads
Description: Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.